Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
NCT ID: NCT00899327
Last Updated: 2009-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at biomarkers in patients at risk of developing myelodysplastic syndrome or other disorders and in healthy participants.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
NCT05588154
Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia
NCT01139307
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
NCT02958462
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
NCT02269592
Biology Studies of Hematologic Cancers
NCT00923442
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To identify novel biomarkers of disease that would help in the initial diagnosis of myelodysplastic syndromes (MDS).
Secondary
* To understand the genesis of anemia in cancers.
* To identify novel biomarkers of disease that predict progression of MDS to acute myeloid leukemia.
OUTLINE: Blood and bone marrow samples are collected. Hemopoietic stem cells (HSC) and progenitor cells are isolated from samples for analysis. Some of these HSC and progenitor cells are used for functional assays. From the rest of the cells, DNA, RNA, and protein is extracted for molecular analyses, including gene mutation analysis, gene methylation assays, chromatin immunoprecipitation, microarray, and real-time polymerase chain reaction.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA methylation analysis
RNA analysis
cytogenetic analysis
gene expression analysis
mutation analysis
polymerase chain reaction
protein expression analysis
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must meet 1 of the following criteria:
* Being investigated for a potential blood disorder due to abnormal blood count
* Patients with a known blood disorder who are having a bone marrow sample taken as part of the assessment of that disorder
* Patients undergoing hip replacement surgery at Nuffield Orthopaedic Centre, Oxford meeting the following criteria:
* Not on treatment likely to impair bone marrow function
* No history of having had treatment likely to have impaired bone marrow function
* Normal blood count
* Archived samples from patients with known blood disorder
PATIENT CHARACTERISTICS:
* See Disease Characteristics
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oxford University Hospitals NHS Trust
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vyas Paresh, MD
Role: PRINCIPAL_INVESTIGATOR
Oxford University Hospitals NHS Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oxford Radcliffe Hospital
Oxford, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MRC-MDS-BIO1
Identifier Type: -
Identifier Source: secondary_id
EU-20852
Identifier Type: -
Identifier Source: secondary_id
CDR0000595855
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.